Key Drivers
- Strong liquidity
- No revenue
- High cash burn
AIAI Summary
PHVS now looks less like a cash-strapped biotech and more like a pre-commercial, catalyst-driven angioedema platform with runway into 2028, but the stock still hinges on one binary value chain—CHAPTER-3 data and NDA execution—while dilution and commercialization burn remain the main overhangs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •High cash burn
PHVS has strong liquidity and minimal leverage, but the lack of revenue, persistent losses, and heavy cash burn make the equity story dependent on external financing rather than operations.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Momentum build
- •Choppy pullback
PHVS has stayed in a constructive uptrend over the last month with higher lows and improving momentum, but it still needs to hold the $33.0–$33.3 area and reclaim $34.5–$34.7 to confirm the breakout.
Recent stall from $34.71 to $33.86 shows short-term reversal risk
Sentiment & News
Key News Insights:
- •AGM Notice
- •EAACI Data
- •HAE Focus
Pharvaris announced its June AGM and showcased EAACI 2026 data supporting deucrictibant's differentiated HAE profile, underscoring steady progress in its angioedema program.
The updates are modestly constructive for PHVS, reinforcing clinical visibility and ongoing shareholder engagement without changing the near-term catalyst picture
Similar Companies in Healthcare
Other companies in the same sector with AI ratings